ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Pier Luigi Zinzani, Jiå Mayer, Christopher R. Flowers, Fontanet Bijou, Ana C. De Oliveira, Yuqin Song, Qingyuan Zhang, Michele Merli, Krimo Bouabdallah, Peter Ganly, Huilai Zhang, Roderick Johnson, Alejandro Martín García-Sancho, Mariano Provencio Pulla, Marek Trněný, Sam Yuen, Herve Tilly, Edwin Kingsley, Gayane Tumyan, Sarit E. AssoulineRebecca Auer, Elena Ivanova, Pil Kim, Sha Huang, Richard Delarue, Judith Trotman

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences